Documentos para Download:

• DIR 2024 Saudi Guideline for Community acquired pneumonia
• DIR AAOS Appropriate Use Criteria for the Prevention of Orthopaedic Infection in Patients Undergoing Dental Procedures
• DIR AAOS Diagnosis and Prevention of Periprosthetic Joint Infections Clinical Practice Guideline
• DIR AAOS Systematic Literature Review on the Management of Surgical Site Infections
• DIR Acute respiratory infection in over 16s: initial assessment and management including virtual wards (hospital at home)
• DIR Adalimumabe — Uveítes não infecciosa intermediária, posterior e pan-uveítes ativa
• DIR Adalimumabe — Uveítes não infecciosa intermediária, posterior e pan-uveítes inativa
• DIR Adalimumabe — Uveítes não infecciosas em crianças e adolescentes não associadas à artrite idiopática juvenil
• DIR Ampliação de uso — Exame para tipificação do alelo HLA-B, para pessoas vivendo com HIV/aids (PVHA) com indicação de uso do antirretroviral Abacavir (ABC)
• DIR Analysis of surgical antibiotic prophylaxis
• DIR Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level
• DIR Antibiótico inalatório (tobramicina) — Colonização das vias aéreas em pacientes com fibrose cística
• DIR Antibiotic Prophylaxis in Oral Surgery for Prevention of Surgical Site Infection (2nd Edition)
• DIR Antibiotic surgical prophylaxis of patients colonised by multidrug-resistant bacteria
• DIR Antibiotic surgical prophylaxis regimens among patients colonised by MDR-GNB and MDR-GPB
• DIR Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
• DIR Antimicrobial stewardship
• DIR Antimicrobial stewardship: changing risk-related behaviours in the general population
• DIR Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use
• DIR Antirretrovirais (ARV) Didanosina Entérica (ddI EC) 250mg — HIV/Aids
• DIR Antirretrovirais (ARV) Didanosina Entérica (ddI EC) 400mg — HIV/Aids
• DIR Antirretrovirais (ARV) Fosamprenavir (FPV) 700m — HIV/Aids
• DIR Antirretroviral etravirina 200mg — Infecção pelo HIV
• DIR Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country
• DIR Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis
• DIR Australian Guidelines for the Prevention and Control of Infection in Healthcare (2019)
• DIR Banlanivimabe + etesevimabe — Pacientes adultos de alto risco infectados por SARS-CoV-2
• DIR Baricitinibe — Tratamento de pacientes adultos com Covid-19 hospitalizados que necessitam de oxigênio por máscara ou cateter nasal, ou que necessitam de alto fluxo de oxigênio ou ventilação não invasiva
• DIR Bedaquilina — Tuberculose resistentes à rifampicina, multirresistentes e extensivamente resistentes a medicamentos
• DIR Bictegravir + entricitabina + tenofovir alafenamida — Tratamento de pacientes com infecção pelo HIV-1 virologicamente suprimidos e com doença renal crônica
• DIR Bictegravir 50mg/entricitabina 200mg/tenofovir alafenamida 25mg — HIV
• DIR Casirivimabe + imdevimabe — Pacientes de alto risco infectados por SARS-CoV-2
• DIR Casirivimabe + imdevimabe — Pacientes infectados por SARS-CoV-2 não hospitalizados de alto risco
• DIR Ceftriaxona 500mg injetável — Sífilis
• DIR Cellulitis and erysipelas: antimicrobial prescribing
• DIR Cilgavimabe + tixagevimabe — Profilaxia pré-exposição à Covid-19, em indivíduos adultos e pediátricos (com 12 anos de idade ou mais, pesando pelo menos 40 kg)
• DIR Clinical management of COVID-19
• DIR Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America
• DIR Clinical practice guideline for Urinary Tract Infection in Paediatric Population
• DIR Clinical practice guidelines for influenza
• DIR Cloridrato de clindamicina cápsula 300 mg — Malária
• DIR Clostridioides difficile infection: antimicrobial prescribing
• DIR ​Community acquired pneumonia
• DIR Consensus Document for the Diagnosis of Prosthetic Joint Infections: A Joint Paper by the EANM, EBJIS, and ESR (With ESCMID Endorsement)
• DIR Consolidated guidelines on differentiated HIV testing services
• DIR Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring
• DIR Consolidated guidelines on HIV testing services, 2019
• DIR Cough (acute): antimicrobial prescribing
• DIR COVID-19 guideline: Management of the long-term effects of COVID-19 (SIGN CPG 161)
• DIR COVID-19 rapid guideline: delivery of systemic anticancer treatments (NG161)
• DIR COVID-19 rapid guideline: managing COVID-19
• DIR COVID-19 rapid guideline: managing the long-term effects of COVID-19
• DIR COVID-19 rapid guideline: vitamin D (NG187)
• DIR Cultura líquida automatizada — Detecção de micobactérias e teste de sensibilidade aos antimicrobianos utilizados no tratamento da tuberculose
• DIR Darunavir (DRV) — Tratamento da infecção pelo HIV
• DIR Darunavir 800 mg — Pessoas vivendo com HIV em falha virológica ao esquema de primeira linha e sem mutações que conferem resistência ao darunavir (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V ou L89V).
• DIR Darunavir de 600mg, comprimidos revestidos, como terapia antirretroviral — Adultos infectados pelo HIV/Aids
• DIR Defining Breakthrough Invasive Fungal infection-Position Paper of the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology
• DIR Delamanida — Tuberculose multirresistente e tuberculose com resistência extensiva, condicionado a apresentação de dados de vida real
• DIR Desinvestimento do medicamento artemeter — Malária Grave
• DIR Diagnosing and managing disseminated histoplamsosis among people living with HIV
• DIR Diagnosis, Management & Prevention of Infective Endocarditis
• DIR Diagnosis and management of gonorrhoea and syphilis
• DIR Diagnosis and Management of Sepsis
• DIR Dicloridrato de quinina solução injetável 300 mg/mL — Malária
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 1: Uso de oxigênio, intubação orotraqueal e ventilação mecânica
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 2: Tratamento Medicamentoso
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 2: Tratamento Medicamentoso
• DIR Diretrizes Brasileiras — Tratamento Hospitalar do Paciente com Covid-19 - Capítulo 4: Assistência Hemodinâmica e Medicamentos Vasoativos
• DIR Diretrizes Brasileiras — Tratamento Medicamentoso Ambulatorial do Paciente com Covid-19
• DIR Dolutegravir (DTG) — Tratamento da infecção pelo HIV
• DIR Dolutegravir — Coinfectados com HIV e tuberculose
• DIR Dolutegravir 5 mg — Tratamento complementar ou substitutivo em crianças de 2 meses a 6 anos de idade com HIV
• DIR Dolutegravir sódico — 3ª linha de tratamento da infecção pelo HIV (vírus de imunodeficiência humana)
• DIR Doxiciclina 100 mg — Profilaxia pós-exposição na prevenção das infecções sexualmente transmissíveis (ISTs) bacterianas, clamídia e sífilis
• DIR Doxiciclina 100mg comprimidos — Sífilis
• DIR EAN-ESCMID guidelines on the diagnosis and management of encephalitis in adults caused by infection
• DIR EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic
• DIR Early childhood pacifier use in relation to breastfeeding, SIDS, infection and dental malocclusion (Best Practice 9(3))
• DIR Effectiveness and Safety of Influenza Vaccination During Pregnancy (Best Practice 18(13))
• DIR EFNS-ENS guidelines for the use of PCR technology for the diagnosis of infections of the nervous system
• DIR EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults
• DIR epic4: Guidelines for the prevention of healthcare-associated infections
• DIR ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
• DIR ESCMID/EUCIC clinical practice guidelines on perioperative antibiotic prophylaxis in patients colonized by multidrug-resistant Gram-negative bacteria before surgery
• DIR ESCMID Clinical Guidelines on the Evaluation and Management of a Reported Antibiotic Allergy
• DIR ESCMID COVID-19 guidelines: diagnostic testing for SARS-CoV-2
• DIR ESCMID COVID-19 living guidelines: drug treatment and clinical management
• DIR ESCMID Generic Competencies in Antimicrobial Prescribing and Stewardship: Towards a European Consensus
• DIR ESCMID guideline: diagnosis and treatment of acute bacterial meningitis
• DIR ESCMID guideline for the diagnosis and management of Pneumocystis pneumonia
• DIR ESCMID guideline for the diagnosis and treatment of biofilm infections 2014
• DIR ESCMID guideline on clinician-targeted interventions to optimise treatment for common acute infections in primary care
• DIR ESCMID guidelines for management of invasive group A streptococcal infections in adult and paediatric patients
• DIR ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug‐resistant Gram‐negative bacteria in hospitalized patients
• DIR ESCMID guidelines on dosing of antimicrobials in patients with renal impairment with or without RRT
• DIR ESCMID guidelines on infection Control Strategies and Interventions to prevent Ventilator-associated Pneumonia in adult patients
• DIR ESCMID guidelines on selection and duration of antibiotic treatment in infectious aortitis and vascular graft and endograft infections
• DIR ESCMID guidelines on testing for SARS-CoV-2 in asymptomatic individuals to prevent transmission in the health care setting
• DIR ESCMID Guidelines on Vaccination of Adult Solid-Organ Transplant Recipients
• DIR ESCMID rapid guidelines for assessment and management of long COVID
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Agents Targeting Lymphoid Cells Surface Antigens [I]: CD19, CD20 and CD52)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Intracellular Signaling Pathways: Tyrosine Kinase and mTOR Inhibitors)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Introduction)
• DIR ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the Safety of Targeted and Biological Therapies: An Infectious Diseases Perspective (Soluble Immune Effector Molecules [I]: Anti-Tumor Necrosis Factor-α Agents)
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) and European Confederation of Medical Mycology (ECMM) 2013 joint guidelines on diagnosis and management of rare and emerging fungal diseases
• DIR European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
• DIR European Society of Clinical Microbiology and Infectious Diseases/European Committee on infection control clinical guidelines on pre-operative decolonization and targeted prophylaxis in patients colonized by multidrug-resistant Gram-positive bacteria b...
• DIR European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
• DIR European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection
• DIR European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
• DIR European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European association of hospital pharmacists)
• DIR European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease
• DIR European society of Clinical Microbiology and Infectious Diseases guidelines on diagnosis and treatment of brain abscess in children and adults
• DIR Expert Consensus on Competency Enhancement of Pertussis Prevention, Diagnosis and Management For Healthcare Professionals Based on the Concept of Medical-Preventive Integration
• DIR Expert Consensus on Vaccination for Patients Receiving Targeted Immunotherapy
• DIR Flucitosina — Meningite criptocócica e demais formas de neurocriptococose
• DIR Flu vaccination: increasing uptake
• DIR Flu vaccination: increasing uptake
• DIR Focused Guidelines for the Surveillance and Control of Candida Infections in Healthcare Institutions: Addressing Key Clinical Questions
• DIR Fosfato de clindamicina solução injetável 150 mg/mL — Malária
• DIR Fostensavir trometamol 600 mg — Adultos vivendo com HIV multirresistente aos antirretrovirais
• DIR Ganciclovir — Profilaxia e tratamento de infecções pelo citomegalovírus (CMV) em pacientes imunossuprimidos pelo HIV
• DIR Guidance document for prevention of Clostridium difficile infection in acute healthcare settings
• DIR Guideline on management of pneumonia and diarrhoea in children up to 10 years of age
• DIR Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV
• DIR Guidelines for HIV post-exposure prophylaxis
• DIR Guidelines for Oropharyngeal Candidiasis in HIV-Negative Individuals
• DIR Guidelines for the clinical management of severe illness from influenza virus infections
• DIR Guidelines for the diagnosis and management of neurological complications of HIV infection
• DIR Guidelines for the management of adult lower respiratory tract infections
• DIR Guidelines for the management of asymptomatic sexually transmitted infections
• DIR Guidelines for the management of symptomatic sexually transmitted infections
• DIR Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection
• DIR Guidelines for the prevention of bloodstream infections and other infections associated with the use of intravascular catheters. Part I
• DIR Guidelines on long-acting injectable cabotegravir for HIV prevention
• DIR Hanseníase
• DIR Healthcare-associated infections
• DIR Healthcare-associated infections: prevention and control (PH36)
• DIR Healthcare-associated infections: prevention and control in primary and community care
• DIR Healthcare workers’ perceptions of risk from exposure to emerging acute respiratory infectious diseases (Best Practice 16(2))
• DIR Hemoperfusion with polymyxin-B for the treatment of abdominal sepsis by Gram-negative bacteria
• DIR Hepatitis B and C testing: people at risk of infection (PH43)
• DIR HIV/AIDS (HIV). Evidence-Based Nutrition Practice Guideline
• DIR HIV testing: encouraging uptake
• DIR HIV testing: increasing uptake among people who may have undiagnosed HIV
• DIR Human and animal bites: antimicrobial prescribing
• DIR Impetigo: antimicrobial prescribing
• DIR Incorporação da pirazinamida 150mg, apresentação dispersível, na Relação Nacional de Medicamentos Essenciais (RENAME) — Tuberculose (TB) causada por Mycobacterium tuberculosis em crianças menores de dez anos ou adultos com dificuldade de deglutição.
• DIR Incorporating Ethics in Clinical Guidelines in Infectious Diseases: A Scoping Review
• DIR Incorporating ethics into infectious disease clinical practice guidelines
• DIR Infection prevention and control
• DIR Insect bites and stings: antimicrobial prescribing
• DIR International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Dise...
• DIR International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the Europe...
• DIR Isoniazida 300 mg — Infecção latente por Mycobacterium tuberculosis
• DIR Joint EANM/ESNR and ESCMID-endorsed Consensus Document for the Diagnosis of Spine Infection (Spondylodiscitis) in Adults
• DIR Leg ulcer infection: antimicrobial prescribing
• DIR Lignes directrices pour l'évaluation économique des programmes de vaccination au
• DIR Management of Acute Orofacial Infection of Odontogenic Origin in Children
• DIR Management of Dengue Infection in Adults (Third Edition)
• DIR Management of Drug Resistant-Tuberculosis
• DIR Management of HIV infection in Children
• DIR Management of HIV Infection in Pregnant Women
• DIR Management of Post Operative Infectious Endophthalmitis
• DIR Management of short-term indwelling urethral catheters to prevent urinary tract infections (Best Practice 14(12))
• DIR Management of Short Term Indwelling Urethral Catheters to Prevent Urinary Tract Infections (Best Practice 4(1))
• DIR Management of suspected bacterial lower urinary tract infection in adult women (SIGN CPG 160)
• DIR Management of suspected bacterial urinary tract infection in adults (SIGN CPG 88)
• DIR Management of Tuberculosis (3rd Edition)
• DIR Manejo da Infecção pelo HIV em Adultos - Módulo 1
• DIR Manejo da Infecção pelo HIV em Adultos - Módulo 2
• DIR Manejo da Infecção pelo HIV em Crianças e Adolescentes - Módulo 1
• DIR Manejo da Infecção pelo HIV em Crianças e Adolescentes - Módulo 2
• DIR Meningitis (bacterial) and meningococcal disease
• DIR Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
• DIR Meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG102)
• DIR Metotrexato — uveítes não infecciosas e de não incorporar o micofenolato de mofetila para o tratamento de uveítes não infecciosas
• DIR Microbiological disgnosis of bloodstream infections
• DIR Molgramostrim 300mcg injetável — Doença pelo HIV
• DIR Molnupiravir — Pacientes infectados por SARS-CoV-2 não hospitalizados com alto risco de agravamento da doença
• DIR Neonatal infection
• DIR Neonatal infection: antibiotics for prevention and treatment
• DIR Neutropenic sepsis: prevention and management in people with cancer
• DIR Nirmatrelvir/ritonavir — Covid-19 nos seguintes grupos de pacientes com sintomas leves a moderados, que não requerem oxigênio suplementar, independentemente do status vacinal: a) imunocomprometidos com idade ≥ 18 anos (segundo os critérios utilizados para
• DIR Nirmatrelvir/ritonavir — Para o tratamento da Covid-19 para pacientes com sintomas leves a moderados, que não requerem oxigênio suplementar, independentemente do status vacinal e com idade ≥ 65 anos ou imunocomprometidos com idade ≥ 18 anos
• DIR Otitis media (acute): antimicrobial prescribing
• DIR Palivizumabe — Prevenção da infecção pelo vírus sincicial respiratório
• DIR Palivizumabe para a Prevenção da Infecção pelo Vírus Sincicial Respiratório (Protocolo de Uso)
• DIR Penicilina benzantina — Prevenção da sífilis congênita
• DIR Pneumonia (community-acquired): antimicrobial prescribing (NG138)
• DIR Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)
• DIR Pneumonia: diagnosis and management
• DIR Pneumonia in adults: diagnosis and management (CG191)
• DIR Podofilotoxina 1,5 mg/g e imiquimode 50 mg/g — Condilomas acuminados decorrentes de infecção por papilomavírus humano (HPV)
• DIR Pretomanida — Tuberculose resistente a medicamentos
• DIR Prevenção da Transmissão Vertical do HIV, Sífilis e Hepatites Virais
• DIR Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics
• DIR Profilaxia Pós-Exposição de Risco (PEP) à Infecção pelo HIV
• DIR Profilaxia Pré-Exposição (PrEP) Oral à Infecção pelo HIV
• DIR Prophylactic strategies to prevent post-intravitreal injection endophthalmitis (PIE): a protocol for a clinical practice guideline
• DIR Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures
• DIR Prostatitis (acute): antimicrobial prescribing
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis (IST)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Infecção pelo HIV (PEP)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Infecções sexualmente transmissíveis
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos: Módulo 1 - Tratamento
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Adultos: Módulo 2 - Coinfecções e Infecções Oportunistas
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes Módulo 1 - Diagnóstico, manejo e acompanhamento de crianças expostas ao HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Manejo da Infecção pelo HIV em Crianças e Adolescentes Módulo 2: Diagnóstico, manejo e tratamento de crianças e adolescentes vivendo com HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção da transmissão vertical de HIV, Sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção da Transmissão Vertical do HIV, Sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Prevenção Transmissão Vertical de HIV, sífilis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Antirretroviral Pós Exposição de Risco de Infecção ao HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pós-Exposição (PEP) de Risco à Infecção pelo HIV, Infecções Sexualmente Transmissíveis e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pós-Exposição de Risco (PEP) à Infecção pelo HIV, IST e Hepatites Virais
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pré-Exposição (PrEP) de risco à infecção pelo HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia Pré-Exposição (PrEP) Oral à Infecção pelo HIV
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Profilaxia pré-exposição de risco à infecção pelo HIV (Prep)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Uveítes não infecciosas
• DIR Protocolo de Uso Palivizumabe — Palivizumabe para Prevenção da Infecção pelo Vírus Sincicial Respiratório
• DIR Pyelonephritis (acute): antimicrobial prescribing
• DIR Raltegravir — Primeira linha de tratamento de pessoas vivendo com HIV/Aids
• DIR Raltegravir 100 mg granulado — Profilaxia da transmissão vertical do HIV em crianças com alto risco de exposição ao HIV.
• DIR Rational Antibiotic Utilisation in Selected Paediatric Conditions
• DIR Recommendations on the delivery of health services for the prevention and care of sexually transmitted infections
• DIR Reducing sexually transmitted infections
• DIR Rendesivir — Covid-19 hospitalizados com pneumonia e necessidade de suplementação de oxigênio
• DIR Respiratory tract infections (self-limiting): prescribing antibiotics (CG69)
• DIR Responses of caregivers to children under the age of five with fever and living where malaria is endemic (Best Practice 14(6))
• DIR Rifampicina 300 mg + isoniazida 150 mg — Tuberculose sensível
• DIR Rifapentina + isoniazida — Infecção Latente pelo Mycobacterium Tuberculosis (ILTB)
• DIR Ritonavir cápsula gelatinosa (mole) termolábil — Infecção pelo HIV
• DIR Rituals and behaviours in the operating theatre – joint guidelines of the Healthcare Infection Society and the European Society of Clinical Microbiology and Infectious Diseases
• DIR Screening for Carriage of Carbapenem-Resistant Enterobacteriaceae in Settings of High Endemicity: A Position Paper From an Italian Working Group on CRE Infections
• DIR Sepsis: recognition, diagnosis and early management (NG51)
• DIR SEXUALLY TRANSMITTED DISEASES. SITUATION IN THE BASQUE AUTONOMOUS COMMUNITY. EFFECTIVENESS OF PREVENTIVE MEASURES
• DIR Sexually transmitted infections: condom distribution schemes
• DIR Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1)
• DIR Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians
• DIR Sinusitis (acute): antimicrobial prescribing
• DIR Sore throat (acute): antimicrobial prescribing
• DIR Sperm washing in serodiscordant HIV couples for use in assisted human reproduction techniques
• DIR Staying Healthy: Preventing infectious diseases in early childhood education and care services (5th Edition)
• DIR Sulfato de quinina comprimido 500 mg — Malária
• DIR Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
• DIR Suspected acute respiratory infection in over 16s: assessment at first presentation and initial management
• DIR Tafenoquina — Malária por Plasmodium vivax
• DIR Tafenoquina — Malária vivax
• DIR Tafenoquina e teste quantitativo da atividade da enzima glicose-6-fosfato desidrogenase (G6PD) — Malária por Plasmodium vivax
• DIR Teste de dosagem de adenosina deaminase — Diagnóstico precoce de tuberculose extrapulmonar
• DIR Teste de fluxo lateral — Detecção de lipoarabinomanano em urina (LF-LAM) para rastreamento e diagnóstico de tuberculose ativa em pessoas suspeitas vivendo com HIV/AIDS
• DIR Teste de Liberação de Interferon-gama (IGRA) — Detecção de infecção latente pelo Mycobacterium tuberculosis em pacientes com doenças inflamatórias imunomediadas ou receptores de transplante de órgãos sólidos
• DIR Teste de liberação interferon-gama (interferon gamma release assay - IGRA) — Detecção de tuberculose latente em pacientes imunocomprometidos
• DIR Teste diagnóstico, point of care, de Cryptococcal Antigen Lateral Flow Assay (CRAG-LFA) — Detecção de infecção por Cryptococcus e diagnóstico de meningite criptocócica em pessoas vivendo com o vírus da imunodeficiência humana (PVHIV)
• DIR Teste PCR multiplex — Detecção de múltiplos agentes bacterianos, virais e fúngicos, causadores de meningites e encefalites.
• DIR Teste qualitativo in vitro, por amplificação de DNA e hibridização reversa em fita de nitrocelulose — Detecção de Mycobacterium leprae resistente a rifampicina, dapsona ou ofloxacino em pacientes acometidos por hanseníase e com suspeita de resistência a a
• DIR Testes comerciais de sondas em linha — Detecção do complexo Mycobacterium tuberculosis (MTB), de mutações nas regiões determinantes de resistência a rifampicina e isoniazida (1ª linha) e a fluoroquinolonas e aminoglicosídeos (2ª linha)
• DIR Testes ELISA — Diagnóstico de sífilis
• DIR Testes EQl — Diagnóstico de sífilis
• DIR Testes RPR — Diagnóstico de sífilis
• DIR Testes TRUST — Diagnóstico de sífilis
• DIR Teste Xpert MTB/RIF — Diagnóstico de casos novos de tuberculose e detecção de resistência à rifampicina
• DIR The update of the 2021 ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli
• DIR Tocilizumabe — Tratamento de pacientes adultos com Covid-19 hospitalizados
• DIR Tuberculosis
• DIR Tuberculosis
• DIR Updated recommendations for the treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum (syphilis) and new recommendations on syphilis testing and partner services
• DIR Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring
• DIR Updated recommendations on service delivery for the treatment and care of people living with HIV
• DIR Updated recommendations on treatment of adolescents and children with chronic HCV infection, and HCV simplified service delivery and HCV diagnostics
• DIR Update of the 2014 ESCMID guidelines for the management of the infection prevention & control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients
• DIR Urinary tract infection (catheter-associated): antimicrobial prescribing
• DIR Urinary tract infection (lower): antimicrobial prescribing
• DIR Urinary tract infection (recurrent): antimicrobial prescribing
• DIR Urinary tract infection in children and young people
• DIR Urinary tract infection in under 16s: diagnosis and management
• DIR Urinary tract infections appropriate diagnosis and antibiotic use for uncomplicated cystitis and pyelonephritis
• DIR Urinary tract infections in adults
• DIR Use of N95, Surgical, or Cloth Masks to Prevent COVID-19 in Health Care and Community Settings: Living Practice Points From the American College of Physicians (Version 1)
• DIR Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper From the European Society of Clinical Microbiology and Infectious Diseases
• DIR Uveítes não Infecciosas
• DIR Vaccine uptake in the general population
• DIR Vaccine uptake in under 19s
• DIR Vacina adsorvida difteria, tétano e pertussis (acelular) dTpa — Vacinação de gestantes
• DIR Vacina adsorvida hexavalente acelular — Crianças com até 6 anos, 11 meses e 29 dias imunodeprimidas, com condições clínicas especiais ou com risco aumentado de apresentarem eventos adversos
• DIR Vacina adsorvida meningocócica B (recombinante) — Hemoglobinúria Paroxística Noturna (HPN) que utilizem eculizumabe
• DIR Vacina adsorvida meningocócica B recombinante — Prevenção de doença meningocócica do sorotipo B em crianças menores de 1 ano de idade
• DIR Vacina contra HPV — Prevenção de câncer de colo do útero
• DIR Vacina contra influenza — Portadores de DPOC
• DIR Vacina Covid-19 (Pfizer/BioNTech) — Imunização ativa de crianças na faixa etária de 6 meses a 5 anos incompletos para a prevenção da Covid-19, condicionada ao preço do contrato do Ministério da Saúde vigente e à reavaliação da matéria após fixação de preç
• DIR Vacina da Fiocruz [ChAdOx-1 (Vacina Covid-19 recombinante)] e da Pfizer/Wyeth [BNT162b2 (Vacina Covid-19)] — Prevenção da Covid-19
• DIR Vacina dengue tetravalente (atenuada) — Prevenção de infecção causada pelo vírus da dengue e suas complicações.
• DIR Vacina herpes-zóster — Prevenção do herpes-zóster em idosos com idade ≥ 80 anos e indivíduos imunocomprometidos com idade ≥ 18 anos.
• DIR Vacina Influenza trivalente de alta dose — Prevenção da gripe em idosos com idade maior ou igual a 80 anos
• DIR Vacina meningocócica ACWY (conjugada) — Adolescentes de 11 e 12 anos no Calendário Nacional de Vacinação
• DIR Vacina meningocócica ACWY (conjugada) — Hemoglobinúria Paroxística Noturna (HPN) que utilizem eculizumabe
• DIR Vacina pneumocócica 23-valente — Imunização de idosos com 60 anos ou mais
• DIR Vacina pneumocócica conjugada 13-valente — Doenças pneumocócicas em pacientes de risco
• DIR Vacina Pneumocócica Conjugada 13-valente — Imunização de crianças de até cinco anos de idade contra doença pneumocócica invasiva e pneumonia
• DIR Vacina pneumocócica conjugada 15-valente — Imunização de pacientes de alto risco com ao menos 2 meses de idade contra doença pneumocócica
• DIR Vacina pneumocócica conjugada 20-valente — Imunização de pacientes de alto risco a partir de 5 anos de idade contra doença pneumocócica
• DIR Vacinas pneumocócicas conjugadas — Imunização de crianças até 5 anos de idade contra doença pneumocócica
• DIR Vacina Tetraviral — Para varicela, sarampo, caxumba e rubéola
• DIR Valganciclovir — Profilaxia e tratamento de infecções pelo citomegalovírus (CMV) em pacientes imunossuprimidos pelo HIV
• DIR Washing of HIV positive semen for artificial fertilization: evaluation report
• DIR What is the Antibody Response and Role in Conferring Natural Immunity Following SARS-CoV-2 Infection? Rapid, Living Practice Points from the American College of Physicians
• DIR WHO consolidated guidelines on tuberculosis
• DIR WHO consolidated guidelines on tuberculosis. Module 1
• DIR WHO consolidated guidelines on tuberculosis. Module 2
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 3
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 4
• DIR WHO consolidated guidelines on tuberculosis. Module 5
• DIR WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia
• DIR WHO guidelines for malaria
• DIR WHO guidelines for malaria, 4 August 2025
• DIR WHO guidelines on meningitis diagnosis, treatment and care
• DIR WHO guidelines on the use of chest imaging in COVID-19
• DIR WHO recommendation on prophylactic antibiotics for women undergoing caesarean section
• DIR WHO recommendation on routine antibiotic prophylaxis for women undergoing operative vaginal birth
• DIR WHO recommendations for management of serious bacterial infections in infants aged 0-59 days

Documentos para Download:

• PDF Brca1 e brca2 em câncer de mama
• DIR Abemaciclibe — Câncer de mama precoce, receptor hormonal positivo, receptor do fator de crescimento epidérmico humano 2 (HER2) negativo, linfonodo positivo e com alto risco de recorrência
• DIR Advanced breast cancer: diagnosis and treatment
• DIR Advanced breast cancer: diagnosis and treatment (CG81)
• DIR Breast cancer
• DIR Breast cancer in women: diagnosis, treatment and follow-up
• DIR Breast cancer nutrition
• DIR Breast Cancer Reconstruction Surgery (Immediate and Delayed) Across Ontario: Patient Indications and Appropriate Surgical Options 17-10v2
• DIR Breastfeeding - Promoting and Supporting the Initiation, Exclusivity, and Continuation of Breastfeeding in Newborns, Infants and Young Children, Third Edition
• DIR Breastfeeding programs in acute and primary healthcare settings (Best Practice 15(3))
• DIR Câncer de Mama
• DIR Clinical Practice Guideline on Breastfeeding
• DIR Clinical Utility of Multigene Profiling Assays in Invasive Early-Stage Breast Cancer 4v3
• DIR COST EVALUATION OF THE EARLy BREAST CANCER DETECTION PROGRAMME OF THE AUTONOMOUS COMMUNITy OF THE BASqUE COUNTRY
• DIR Criteria for appropriate use of FDG-PET in breast cancer
• DIR Digital mammograms in breast cancer screening. Assessment of their efficiency and inclusion in the Early Breast Cancer Detection Programme of the Basque Country
• DIR Diretrizes Diagnósticas e Terapêuticas — Carcinoma de Mama
• DIR Diretrizes Diagnósticas e Terapêuticas — Carcinoma de Mama
• DIR Diretrizes Diagnósticas e Terapêuticas — Carcinoma de Mama
• DIR Diretrizes Diagnósticas e Terapêuticas — Carcinoma de Mama
• DIR Diretrizes Nacionais — Detecção Precoce do Câncer de Mama
• DIR Early and locally advanced breast cancer: diagnosis and management
• DIR Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
• DIR EVALUATION OF CARE TIMES FOR THE MAIN CANCER SITES: COLON/RECTUM, LUNG, BREAST AND PROSTATE
• DIR Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer
• DIR Hormonioterapia prévia — Câncer de mama
• DIR Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
• DIR Improving outcomes in breast cancer (CSG1)
• DIR INFORMATION REQUIRED FOR ANALYSING THE IMPACT OF THE EARLY BREAST CANCER DETECTION PROGRAMME
• DIR Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline
• DIR Locoregional Therapy of Locally Advanced Breast Cancer 1-19
• DIR Mamografia — Rastreamento do câncer de mama em mulheres assintomáticas com risco habitual fora da faixa etária atualmente recomendada (50 a 69 anos)
• DIR Management of Breast Cancer (Third Edition)
• DIR Management of ductal carcinoma in situ of the breast
• DIR Management of Male Breast Cancer: ASCO Guideline
• DIR Management of the Axilla in Early-Stage Breast Cancer
• DIR New imaging techniques in the diagnosis of breast cancer: digital mammography and electrical impedance and conductivity
• DIR New percutaneous techniques of histological diagnosis of non palpable lesions suspected of breast cancer
• DIR Optimal Systemic Therapy for Early Female Breast Cancer 1-21
• DIR Pertuzumabe e trastuzumabe em combinação — Combinação de dose fixa subcutânea no tratamento neoadjuvante de pacientes com câncer de mama HER2-positivo
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Câncer de Mama
• DIR Quantitative Image Analysis of HER2 Immunohistochemistry for Breast Cancer
• DIR Radioterapia Intraoperatória — Tumores de Mama
• DIR Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians
• DIR Study on the extension of the age of the target population screening program for breast cancer in the Basque Country
• DIR Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update
• DIR The Management of Nipple Pain and/or Trauma Associated with Breastfeeding (Best practice 7(3))
• DIR The management of nipple pain and/or trauma associated with breastfeeding (Best Practice 13(4))
• DIR The Utility of PET/CT in Breast Cancer (Stages II-IV): An Evidence Summary 14
• DIR Trastuzumabe — Câncer de mama avançado
• DIR Trastuzumabe — Câncer de mama HER2-positivometastático em primeira linhade tratamento
• DIR Trastuzumabe — Câncer de mama inicial
• DIR Trastuzumabe entansina — Tratamento adjuvante do câncer de mama HER2-positivo operado em estádio III com doença residual na peça cirúrgica após tratamento neoadjuvante
• DIR Treatment of primary breast cancer (SIGN CPG 134)
• DIR Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer 1-22-Av2
• DIR Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update
• DIR Women’s perceptions and experiences of breastfeeding support (Best Practice 14(7))

Documentos para Download:

• DIR AAOS/METRC Clinical Practice Guideline on Management of Acute Compartment Syndrome
• DIR AAOS CLINICAL PRACTICE GUIDELINE FOR EVALUATION OF PSYCHOSOCIAL FACTORS INFLUENCING RECOVERY FROM ADULT ORTHOPAEDIC TRAUMA
• DIR Ácido meso2,3-dimercaptossuccínico (DMSA, succimer) — Intoxicação aguda por mercúrio
• DIR Analysis of the appropiateness of hospital admissions from emergencies
• DIR Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services
• DIR Clinical Practice Guideline for the Management of Communication and Swallowing Disorders following Paediatric Traumatic Brain Injury
• DIR Clinical Practice Guidelines for the diagnosis and treatment of non-serious blunt chest trauma
• DIR Cloridrato de hidroxocobalamina na concentração de 5g injetável — Intoxicações por cianeto
• DIR Crisis Intervention for Adults Using a Trauma-Informed Approach: Initial Four Weeks of Management Third Edition
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 1
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 2
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 3
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 4
• DIR Diagnóstico e tratamento de intoxicações por agrotóxicos - Capítulo 5
• DIR Diretrizes Brasileiras — Diagnostico e Tratamento de Intoxicações por Agrotóxicos – Capítulo 2
• DIR Diretrizes Brasileiras — Diagnósticos e tratamento de intoxicações por agrotóxicos - Capítulo 1
• DIR Diretrizes Brasileiras — Intoxicações por agrotóxicos - Capítulo 3
• DIR Diretrizes Brasileiras — Intoxicações por Agrotóxicos - Capítulo 4
• DIR Diretrizes Brasileiras — Intoxicações por Agrotóxicos - Capítulo 5
• DIR EFNS guideline on mild traumatic brain injury: report of an EFNS task force
• DIR Emergency and acute medical care in over 16s
• DIR Emergency and acute medical care in over 16s: service delivery and organisation
• DIR Hidroxocobalamina na intoxicação aguda por cianeto (Protocolo de Uso)
• DIR Iodeto de Potássio na Emergência Nuclear
• DIR Major trauma: assessment and initial management
• DIR Major trauma: service delivery
• DIR Mild traumatic brain injury
• DIR Monitorização intracraniana PIC Cateter de fibra óptica (tipo CAMINO) — Monitorização da pressão intracraniana em pacientes com traumatismo cranioencefálico grave
• DIR Monitorização intracraniana PIC Cateter PTIO2, cateteres com ponta metálica (tipo CODMAN ou PRESSIO) — Monitorização da pressão intracraniana em pacientes com traumatismo cranioencefálico grave
• DIR Post-traumatic stress disorder
• DIR Rehabilitation after traumatic injury
• DIR STUDY OF URGENT AND EMERGENCY HEALTH SERVICES IN THE BASQUE AUTONOMOUS COMMUNITY: ANALYSIS AND PROPOSALS FOR IMPROVEMENT
• DIR Terapia por pressão subatmosférica (VAC) — Lesões traumáticas agudas extensas
• DIR The experiences of elderly patients receiving care in the emergency department (Best Practice 16(9))
• DIR Trauma

Documentos para Download:

• DIR «BATERA ZAINDUZ»: IMPLEMENTATION OF CHRONIC DISEASE MANAGE-MENT MODELS IN PRIMARY CARE, FOCUSED ON THE INTEGRATION OF AS-SISTANCE
• DIR ANALYSIS AND DEVELOPMENT OF PREVENTIVE ACTIVITIES IN PRIMARY CARE. REVIEW OF THE PREFERENTIAL OFFER AND ITS SUPPORT SOFTWARE (PAP)
• DIR Analysis of telemedicine applications in the management-coordination of specilised and primary care. Appraisal of results and costs of pre-existing experiences (teleophthalmology)
• DIR Analysis of the use of clinical protocols for monitoring the chronically ill in primary health care
• DIR ASSESSMENT OF FACTORS RELATED TO THE PHARMACEUTICAL EXPENDITURE IN PRIMARY CARE, AND PRESCRIPTION QUALITY IN CHRONIC DISEASES
• DIR FINANCING PROCEDURES IN PRIMARY CARE ADEQUATE FOR RESOURCES AND EFFICIENCY, BY MEANS OF ADJUSTED CLINICAL GROUPS (ACG)
• DIR Recommandation relative au dépistage de la chlamydia et de la gonorrhée en soins primaires chez les personnes non connues comme appartenant à un groupe à risque
• DIR Routine analysis requesting profiles in Primary Health Care: comparison of guidelines and, variability and cost analysis in the Basque Country
• DIR THE COORDINATION BETWEEN PRIMARY AND SPECIALISED HEALTHCARE FROM THE POINT OF VIEW OF THE PROFESSIONALS
• DIR USEFUL STRATEGIES FOR PROMOTING HEALTHY LIFESTYLES IN PRIMARY HEALTHCARE

Documentos para Download:

• DIR Exercise for People with Cancer 19-5v2
• DIR Physical activity: brief advice for adults in primary care (PH44)
• DIR Physical activity: encouraging activity in the community
• DIR Physical activity: exercise referral schemes (PH54)
• DIR Physical activity: for NHS staff, patients and carers
• DIR Physical activity: walking and cycling (PH41)
• DIR Physical activity and the environment
• DIR Promoting physical activity for children and young people (PH17)
• DIR Supportive treatment for cancer - Part 1: exercise treatment
• DIR WHO guidelines on physical activity and sedentary behaviour

Documentos para Download:

• PDF COVID-19 E ASSOCIAÇÃO COM O TRABALHO
• PDF (ANEXO I) COVID-19 E ASSOCIAÇÃO COM O TRABALHO
• PDF Violência no trabalho – mapeamento epidemiológico e intervenção preventiva
• PDF Depressão em meio ocupacional: rastreamento e tratamento
• PDF Uso de cinta, suporte ou órtese lombar prevenção da lombalgia ocupacional
• PDF Rastreamento por eletrocardiograma – acidentes, morte súbita, síncope e trabalho
• PDF Asma e trabalho diagnóstico por medida seriada do peak flow
• PDF Epilepsia e trabalho: rastreamento
• PDF Efeito do rastreamento do uso de álcool e drogas entre trabalhadores
• DIR Clinical Guideline for the Diagnosis and Management of Work-related Mental Health Conditions in General Practice
• DIR Healthy workplaces: improving employee mental and physical health and wellbeing
• DIR Mental wellbeing in over 65s: occupational therapy and physical activity interventions (PH16)
• DIR Promoting physical activity in the workplace (PH13)
• DIR Safe Handling of Hazardous Drugs 16-3v3
• DIR Teste qualitativo — Detecção de fibronectina fetal para diagnóstico do trabalho de parto prematuro
• DIR Updating of the Shared Work System for Systematic Reviews of the Evidence and Critical Appraisal (FLC 3.0 Platform)
• DIR Workplace health: long-term sickness absence and capability to work
• DIR Workplace health: long-term sickness absence and capability to work
• DIR Workplace health: management practices

Documentos para Download:

• PDF Espasticidade – tratamento com nabilone
• PDF Espasticidade – tratamento com glicina e treonina
• PDF Espasticidade – tratamento com Diazepam ou clonazepam
• PDF Espasticidade – tratamento com Baclofeno
• PDF Espasticidade – avaliação pela medida de independência funcional
• PDF Espasticidade – avaliação pela escala de Tardieu
• PDF Espasticidade – avaliação pela escala de reflexos tendinosos
• PDF Espasticidade – tratamento com tizanidina e/ou clonidina
• PDF Espasticidade - Tratamento com Neurólise com fenol
• PDF Espasticidade – avaliação pela escala de penn
• PDF Espasticidade - Tratamento Com Neurólise por Toxina Botulínica
• PDF Espasticidade – tratamento com dantrolene sódico
• PDF Espasticidade – tratamento com piracetem e levetiracetam
• PDF Espasticidade – avaliação pelo índice de barthel
• PDF Espasticidade – avaliação pela escala modificada de ashworth
• PDF Espasticidade – avaliação pela escala analógica de dor
• PDF Úlceras por pressão: tratamento
• DIR AAOS Appropriate Use Criteria for Limb Salvage or Early Amputation
• DIR Baclofeno oral — Tratamento da espasticidade
• DIR Brain injury rehabilitation in adults (SIGN CPG 130)
• DIR Cancer rehabilitation
• DIR EFNS guidelines on cognitive rehabilitation: report of an EFNS task force
• DIR EFNS Guidelines on cognitive rehabilitation: report of an EFNS Task Force
• DIR Espasticidade
• DIR European physiotherapy benchmark statement
• DIR European Physiotherapy Guidelines for Parkinson’s
• DIR Framework for clinical guideline development in physiotherapy
• DIR Management of patients with stroke: rehabilitation, prevention and management of complications, and discharge planning (SIGN CPG 118)
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Espasticidade
• DIR Protocolo Clínico e Diretrizes Terapêuticas — Espasticidade
• DIR Quality Assurance Standards of Physiotherapy Practice and Delivery
• DIR Rehabilitation after critical illness in adults
• DIR Rehabilitation after critical illness in adults
• DIR Rehabilitation for adults with complex psychosis
• DIR Spasticity in under 19s: management
• DIR Spinal Cord Injury (SCI). Evidence-Based Nutrition Practice Guideline
• DIR Stroke rehabilitation in adults
• DIR Stroke rehabilitation in adults (CG162)
• DIR Tetraidrocanabinol 27mg/ml + canabidiol 25mg/ml — Espasticidade moderada a grave relacionada à esclerose múltipla

Documentos para Download:

• PDF Pacientes em Unidades de Terapia Intensiva Mobilização Precoce
• DIR Effectiveness of non-invasive mechanical ventilation for the treatment of respiratory failure in patients with amyotrophic lateral sclerosis
• DIR ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients
• DIR Eye care for intensive care patients (Best Practice 6(1))
• DIR Interventions to meet family needs of critically ill patients in an adult intensive care unit (Best Practice 16(5))
• DIR Lower UTI in women
• DIR Ventilação mecânica invasiva domiciliar — Insuficiência respiratória crônica

Documentos para Download:

• PDF Protocolo para Elaboração de Laudo Médico Pericial – Perícia Administrativa
• PDF Protocolo para elaboração de Laudo Médico Pericial na área securitária
• PDF Protocolo para elaboração de Laudo Médico Pericial Previdenciário no requerimento de Benefício por Incapacidade
• PDF Diretrizes para se verificar a presença de NEXO CAUSAL em Perícias Médicas junto à Justiça do Trabalho
• PDF Protocolo para Elaboração Laudo Médico Pericial na Justiça do Trabalho
• PDF Protocolo para a elaboração de Laudo Médico Pericial Cível
• PDF Protocolo para a elaboração de Laudo Médico Pericial Criminal
• PDF Diretriz para avaliação do Dano Pessoal - ABMLPM
• DIR Child abuse and neglect
• DIR Child abuse and neglect
• DIR Domestic violence and abuse
• DIR Domestic violence and abuse: multi-agency working (PH50)
• DIR Preventing Violence, Harassment and Bullying Against Health Workers, Second Edition
• DIR Violence and aggression: short-term management in mental health, health and community settings